Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Transfer Factor Oral Solution is a biological immune regulator developed and manufactured by Extrawell Pharmaceutical. It is composed of a complex mixture of low-molecular-weight peptides, nucleotides, and amino acids derived from lymphoid tissues or other immune sources. The drug acts as a dual immune regulator, capable of both stimulating and suppressing immune responses to maintain homeostasis. It is primarily indicated for the treatment of diseases associated with viral infections and a weakened cellular immune system, as well as certain autoimmune conditions. The product is approved and marketed in the People's Republic of China and Hong Kong as part of Extrawell's self-produced product portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Transfer Factor Oral Solution.